These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 992212)

  • 41. Post-translational alterations in newly synthesized cartilage proteoglycans induced by the glutamine analogue 6-diazo-5-oxo-L-norleucine. Time course of inhibition and recovery.
    Clark CC; Richards CF; Iozzo RV
    Biochem J; 1991 Jan; 273(Pt 2)(Pt 2):283-8. PubMed ID: 1991027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glycosaminoglycans: potential determinants in cardiac morphogenesis.
    Markwald RR; Funderberg FM; Bernanke DH
    Tex Rep Biol Med; 1979; 39():253-70. PubMed ID: 553313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Limb development in mouse embryos: protection against teratogenic effects of 6-diazo-5-ox-L-norleucine (DON) in vivo and in vitro.
    Greene RM; Kochhar DM
    J Embryol Exp Morphol; 1975 Apr; 33(2):355-70. PubMed ID: 1176851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Don, conv and donv--I. Inhibition of L-asparagine synthetase in vitro.
    Jayaram HN; Cooney DA; Milman HA; Homan ER; Rosenbluth RJ
    Biochem Pharmacol; 1976 Jul; 25(14):1571-82. PubMed ID: 8046
    [No Abstract]   [Full Text] [Related]  

  • 45. Inhibition of protein glycosylation causes renal dysplasia in the chick embryo.
    Spencer JR; Maizels M
    J Urol; 1987 Oct; 138(4 Pt 2):984-90. PubMed ID: 3309377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
    Sklaroff RB; Casper ES; Magill GB; Young CW
    Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are lysosomes involved in the regression of the male fetal Müllerian ducts?
    Tran D; Josso N
    Biol Reprod; 1981 Nov; 25(4):905-14. PubMed ID: 7306658
    [No Abstract]   [Full Text] [Related]  

  • 48. DON, CONV and DONV-II. Inhibition of L-'asparagine synthetase in vivo.
    Rosenbluth RJ; Cooney DA; Jayaram HN; Milman HA; Homan ER
    Biochem Pharmacol; 1976 Aug; 25(16):1851-8. PubMed ID: 9091
    [No Abstract]   [Full Text] [Related]  

  • 49. Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
    Huber KR; Mayer EP; Mitchell DF; Roberts J
    Br J Cancer; 1987 Jun; 55(6):653-6. PubMed ID: 3620309
    [No Abstract]   [Full Text] [Related]  

  • 50. Corneal development. IV. Interruption of collagen excretion into the primary stroma of the cornea with L-azetidine-2-carboxylic acid.
    Coulombre AJ; Coulombre JL
    Dev Biol; 1972 May; 28(1):183-90. PubMed ID: 5041193
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of hexosamine inhibitors on the secretion of gamma-globulin.
    Esterly NB; Alm GV; Peterson RD; Dorfman A
    Experientia; 1971 Feb; 27(2):208-9. PubMed ID: 5544753
    [No Abstract]   [Full Text] [Related]  

  • 52. DON, CONV and DONV-III. Pharmacologic and toxicologic studies.
    Cooney DA; Jayaram HN; Milman HA; Homan ER; Pittillo R; Geran RI; Ryan J; Rosenbluth RJ
    Biochem Pharmacol; 1976 Aug; 25(16):1859-70. PubMed ID: 9092
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).
    Rahman A; Smith FP; Luc PT; Woolley PV
    Invest New Drugs; 1985; 3(4):369-74. PubMed ID: 4086244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects on DON (6-diazo-5-oxo-L-norleucine) and azaserine on the sand-dollar embryo.
    KARNOFSKY DA; BEVELANDER G
    Proc Soc Exp Biol Med; 1958 Jan; 97(1):32-7. PubMed ID: 13518172
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Casper E
    Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
    Earhart RH; Koeller JM; Davis HL
    Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measuring histological form change with finite element methods: an application using diazo-oxo-norleucine (DON)-treated rats.
    Lozanoff S; Diewert VM
    Am J Anat; 1986 Oct; 177(2):187-201. PubMed ID: 3788820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA damage and repair induced by diazoacetyl derivatives of amino acids with different mechanism of cytotoxicity. Correlations with mutagenicity and carcinogenicity.
    Brambilla G; Cavanna M; Carlo P; Finollo R; Sciaba L; Parodi S; Bolognesi C
    J Cancer Res Clin Oncol; 1979 May; 94(1):7-20. PubMed ID: 468901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultrastructure of the expected fusion zone in rat fetuses with diazo-oxo-norleucine (DON)-induced cleft palate.
    Morgan PR; Pratt RM
    Teratology; 1977 Jun; 15(3):281-9. PubMed ID: 882917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morphogenesis of the collagenous stroma in the chick cornea.
    Trelstad RL; Coulombre AJ
    J Cell Biol; 1971 Sep; 50(3):840-58. PubMed ID: 4329158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.